Clinical outcomes of whole pelvis radiotherapy and stereotactic body radiotherapy boost for intermediate- and high-risk prostate cancer.

CONCLUSIONS: WPRT followed by SBRT boost using Cyberknife in intermediate- and high-risk prostate cancer is feasible with minimal toxicity and encouraging BCF-free survival.
PMID: 26846353 [PubMed - as supplied by publisher]

Source: Clinical Prostate Cancer - February 5, 2016 Category: Cancer & Oncology Authors: Kim HJ, Phak JH, Kim WC Tags: Asia Pac J Clin Oncol Source Type: research